三种PARP抑制剂（奥拉帕利、尼拉帕利和鲁卡帕利）作为铂类治疗反应良好的卵巢癌患者维持治疗的间接比较。 - Suppr

Suppr

超能文献

Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.

作者信息

Mengato Daniele, Cancanelli Luca, Di Spazio Lorenzo, Rivano Melania, Chiumente Marco, Messori Andrea

出版信息

Int J Clin Pharmacol Ther. 2022 Aug;60(8):370-372. doi: 10.5414/CP204243.

DOI:10.5414/CP204243

PMID:35652551

Abstract

摘要

相似文献

Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.

Int J Clin Pharmacol Ther. 2022 Aug;60(8):370-372. doi: 10.5414/CP204243.

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7.

Successful Management of Ovarian Cancer Progressing on Olaparib by Niraparib Following Cytoreduction: A Case Report.

In Vivo. 2024 Mar-Apr;38(2):958-962. doi: 10.21873/invivo.13527.

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.

Pharmacoeconomics. 2019 Mar;37(3):391-405. doi: 10.1007/s40273-018-0745-z.

Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.

J Comp Eff Res. 2019 Jun;8(8):577-587. doi: 10.2217/cer-2018-0069. Epub 2019 Apr 2.

Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.

Gynecol Oncol. 2020 May;157(2):500-507. doi: 10.1016/j.ygyno.2020.02.030. Epub 2020 Mar 13.

Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.

J Med Econ. 2019 Feb;22(2):187-195. doi: 10.1080/13696998.2018.1557199. Epub 2019 Jan 4.

Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.

Curr Drug Targets. 2020;21(2):167-178. doi: 10.2174/1389450120666190925123507.

Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.

Gynecol Oncol. 2024 Feb;181:33-39. doi: 10.1016/j.ygyno.2023.11.037. Epub 2023 Dec 16.

DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.

Int J Gynecol Cancer. 2020 Nov;30(11):1824-1828. doi: 10.1136/ijgc-2020-001694. Epub 2020 Sep 2.

引用本文的文献

Survival analysis of recurrent ovarian cancer under different PARP inhibitor treatment patterns: a single-center retrospective study.

Front Oncol. 2025 Jan 10;14:1504084. doi: 10.3389/fonc.2024.1504084. eCollection 2024.

Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials.

Front Pharmacol. 2024 Sep 18;15:1460285. doi: 10.3389/fphar.2024.1460285. eCollection 2024.

Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses.

Cancers (Basel). 2023 Mar 7;15(6):1633. doi: 10.3390/cancers15061633.

The "One-to-Many" Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma.

Cureus. 2022 Aug 25;14(8):e28369. doi: 10.7759/cureus.28369. eCollection 2022 Aug.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.

作者信息

Mengato Daniele, Cancanelli Luca, Di Spazio Lorenzo, Rivano Melania, Chiumente Marco, Messori Andrea

出版信息

Int J Clin Pharmacol Ther. 2022 Aug;60(8):370-372. doi: 10.5414/CP204243.

DOI:10.5414/CP204243

PMID:35652551

Abstract

摘要